Sign In
NewsRadar

Search Press
Looking for press releases of a particular company? Enter company name (or keyword) here.

   


AMT to present preclinical proof-of-concept data on its gene therapy AMT-020
to treat acute intermittent porphyria


The research, done in collaboration with the Centro de Investigación Médica Aplicada (CIMA) at the University of Navarra, Pamplona, Spain, is being presented at Porphyrins and Porphyrias Congress, Rotterdam, the Netherlands.


Amsterdam, the Netherlands, May 1st 2007 – Amsterdam Molecular Therapeutics BV (AMT), a leader in the field of human gene therapy, will today present preclinical data on its AMT-020 gene therapy to treat acute intermittent porphyria (AIP) at the Porphyrins and Porphyrias Congress, Rotterdam.

The data suggest that AMT-020 has the potential to protect patients suffering from recurrent porphyria attacks and/or neuropathy.

AMT-020 is comprised of an Adeno-Associated Virus (AAV) vector delivering the gene for porphobilinogen deaminase (PBGD). The aim of this study, which was performed by Dr’s Fontanellas, González-Aseguinolaza and Prieto at CIMA, was to investigate the potential of AMT-020 to protect against acute attack induced by phenobarbital (Pb) in a mouse model of AIP. The model reproduces key features of AIP attack after Pb induction, including increased urinary excretion of haem precursors and decreased motor function.

PBGD-deficient female and male mice were intravenously injected with 1x1011 gc/mouse of AMT-020. Control animals received the same AAV vector but carried the luciferase reporter gene.

One month after injection, both groups were treated with an increasing dose of Pb for 4 days to induce a porphyria attack. The results showed that porphyric mice that received AMT-020 had almost normal haem precursors in the urine and normal motor function, indicating that the treatment completely prevented the occurrence of porphyric attacks.

“These results are very encouraging, and show the potential of AMT-020 to treat AIP,” said Sander van Deventer, CSO at AMT, who presented the data. “The next stage in the development of the product will be to confirm the ability of our liver-directed vector technology to induce long-term therapeutic protein expression in non-human primates.”
-ENDS-


About AMT
Amsterdam Molecular Therapeutics BV (AMT) is a gene therapy company founded by scientists of the University of Amsterdam Medical Center (AMC) in 1998. AMT focuses on the development of gene-based therapies for orphan metabolic and ocular diseases. AMT’s long-term gene expression technology is based on specific delivery of therapeutic genes into target organs or tissues. Production of AAV-based gene therapy vectors has been optimized and AMT has developed and validated a unique, stable and scalable GMP production platform. Its lead product, AMT-011, is in phase II for the first indication: treatment of lipoprotein lipase deficiency type I.

The company's Management, Supervisory and Scientific Advisory Board bring together an extensive know-how from both gene science as well as the biotech and pharmaceutical worlds. For further information, go to www.amtbv.com.


About Acute Intermittent Porphyria
Acute intermittent porphyria is a life threatening inherited disease characterised by a partial deficiency of hepatic porphobilinogen deaminase (PBGD). Clinical symptoms include attacks of acute abdominal pain, muscular weakness and a complex array of neurovisceral and psychiatric symptoms. There is also an increased risk of primary liver cancer and renal failure. The attacks are normally triggered when the haem synthesis is induced by infections, stress, alcohol, hormones, or specific drugs. The prevalence of symptomatic disease is 1–2 per 20,000 individuals, however, in some regions of Sweden the prevalence of the disease can be as high as 60-100 cases per 100,000 population. Women are more commonly affected than men.


About the Centro de Investigación Médica Aplicada at the University of Navarra
CIMA is a biomedical research project which aims to improve clinical practice. It was started at the University of Navarra in order to give an organized and<


Publisher Contact Information:

Amsterdam Molecular Therapeutics B.V. (AMT)
+31 20 566 7394
s.vandeventer@amtbv.com

Company profile of Amsterdam Molecular Therapeutics B.V. (AMT)
Past press releases of Amsterdam Molecular Therapeutics B.V. (AMT).

Data


26,152
Tech investments
From our Online Data Service
16,897
VC-backed companies
From our Radar


Recent Deals


DATEAMOUNTSECTOR
Sep 20€8.0MSecurity
Sep 20€3.0MArtificial Intelligence
Sep 20€55.0MInternet services
Sep 20€1.0MContent management
Sep 19€23.0MKnowledge management
Sep 19€2.3MKnowledge management
Sep 19€15.0MDiagnostics

For information on Europe's most extensive database on technology funding click here!

Events



Press Releases


May 28
Identiq
identiq raises $5m seed, launches privacy-first identity validation...

Apr 29
Nethone
nethone raised over $1 million from innovation nest

Oct 1
The Link App
the link app launches version 2.0

Mar 29
Addex Therapeutics
addex sucessfully raises chf40 million in capital increase

Jan 2
Urban Jungle
urban jungle raises Ł1m in seed funding to build tech-enabled home ...





About usContact usLegal Information
Copyright © 1999-2019
Emerging Technology Research Europe Inc. All rights reserved.